American Thoracic Society (ATS) 2016 International Conference

June 6, 2016June 6, 2016

Pulmonary Arterial Hypertension Candidate by Galectin Shows Positive Results

Galectin Therapeutics, Inc. recently reported that GR-MD-02, the company’s lead candidate galectin-3 (gal-3) inhibitor, has demonstrated a positive effect on vascular remodeling in mouse models of pulmonary arterial hypertension (PAH). The ... Read more

May 19, 2016May 19, 2016

Veracyte Shows New Drug Data for IPF Diagnosis at ATS 2016

Idiopathic Pulmonary Fibrosis, News

Veracyte presented data at the recent American Thoracic Society (ATS) 2016 International Conference from a study proving the potential of its Envisia classifier to improve the diagnosis of interstitial lung diseases, ... Read more

May 18, 2016May 18, 2016

Efficacy and Safety of Ofev (Nintedanib) as IPF Treatment Supported by New Analyses

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals presented 12 idiopathic pulmonary fibrosis (IPF)-related abstracts at the recent American Thoracic Society (ATS) 2016 Annual Conference, including further analyses of its INPULSIS clinical trial program, which added to the ... Read more

May 16, 2016May 16, 2016

ATS 2016: Bayer Presents Data on Adempas for Pulmonary Hypertension

News, Pulmonary Hypertension

Bayer is presenting six abstracts at the American Thoracic Society (ATS) 2016 International Conference through May 18 in San Francisco, Calif. The presentations highlight the use of Adempas (riociguat) for pulmonary ... Read more

May 16, 2016May 16, 2016

Aradigm’s Candidates for NCFBE Featured at ATS 2016

Bronchiectasis, Cystic Fibrosis, News

The American Thoracic Society (ATS) is hosting the ATS 2016 International Conference through May 18 in San Francisco, Calif. Aradigm, an emerging pharmaceutical focused on drugs for the prevention and ... Read more

May 13, 2016May 13, 2016

Theravance Poster to Show Phase 3 ATTAIN Trial Results on Pneumonia at ATS 2016

News, Pneumonia

Theravance Biopharma, Inc. recently announced in a press release the presentation of new data on VIBATIV® (telavancin), the company’s FDA-approved antibiotic, at the American Thoracic Society (ATS) 2016 International Conference, May 13-18 in San Francisco. The ... Read more

May 12, 2016May 13, 2016

Veracyte to Show Data on Lung Disease Genomic Classifiers at ATS 2016

Idiopathic Pulmonary Fibrosis, Lung Cancer, News

Veracyte, Inc. will present results at the American Thoracic Society (ATS) 2016 International Conference from multiple trials supporting the company’s genomic tests that may resolve uncertainty in lung disease diagnosis. The company ... Read more

May 10, 2016May 11, 2016

Galectin Therapeutics Preclinical Research on Galectin-3 Role in PAH to be Presented at ATS 2016

News, Pulmonary Hypertension

Galectin Therapeutics, Inc., a biopharmaceutical company that develops therapeutic compounds that bind and inhibit galectin proteins with pathological activity, announced recently that its collaborative abstract on galectin-3 and its role ... Read more